ArticleJournal of Korean Neurosurgical Society2026
Evaluation of Serum Prestin as a Potential Biomarker for Trauma Severity in Patients with Traumatic Brain Injury.
Article in Journal of Korean Neurosurgical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrestin, expressed in cochlear outer hair cells, is essential for auditory signal amplification and may serve as a biomarker for cochlear injury related to trauma. This study aimed to investigate the potential role of prestin in the diagnosis and prognosis of cranial trauma.
methodsA total of 150 participants were included, comprising 110 patients aged 18-70 who were treated for head trauma and 40 age-matched healthy controls. The patients were divided into two groups of 55 each, with Glasgow coma scale (GCS) ≥13 and GCS ≤8, according to the GCS. Prestin was measured by enzyme-linked immunosorbent assay in serum on days 1, 3, and 7 in the patient and also the control groups. In the diagnosis of trauma and determining trauma severity, important risk levels (cut-off values) according to prestin's measurement days were calculated by receiver operating characteristic (ROC) analysis.
resultsPrestin values in both the GCS ≥13 and GCS ≤8 groups were dramatically lower than those in the control on all measurement days. Additionally, prestin values in the GCS ≤8 group on days 3 and 7 tended to be lower than those in the GCS ≥13 group. Furthermore, there was a tendency for serum prestin values to increase as time progressed especially in the GCS ≥13 group. ROC analysis showed that prestin values on the first, third, and seventh days showed high accuracy in detecting traumatized individuals with area under the curve (AUC) values of 85%, 81%, and 75%, respectively (sensitivity : 84%, 79%, and 83%, respectively). Also, prestin data on the first day accurately detected the severity of trauma at a high rate (sensitivity, 82%; AUC, 90%).
conclusionOur findings suggest that serum prestin levels on the first day after trauma may provide supportive information regarding trauma severity. However, further controlled studies are needed before definitive diagnostic or prognostic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.